世界最新医学信息文摘（电子版）
世界最新醫學信息文摘（電子版）
세계최신의학신식문적（전자판）
World Latest Medicine Information
2013年
20期
14-14,20
,共2页
江秀慧%屈非%张全海%张信鸽%杨玉前
江秀慧%屈非%張全海%張信鴿%楊玉前
강수혜%굴비%장전해%장신합%양옥전
尿激酶胸膜腔注入%结核性胸膜炎%疗效观察
尿激酶胸膜腔註入%結覈性胸膜炎%療效觀察
뇨격매흉막강주입%결핵성흉막염%료효관찰
Intrapleural urokinase%tuberculous pleurisy%clinical observation
目的：观察尿激酶胸膜腔注入与传统单纯抗结核治疗结核性胸膜炎的疗效观察。方法选择120例渗出性结核性胸膜炎，随机分为治疗组、对照组各60例。治疗组抗结核治疗同时，间断胸膜腔穿刺抽胸水后，向胸膜腔内注入尿激酶10万 IU，对照组单纯抗结核治疗同时仅间断胸膜腔穿刺抽胸水治疗，分别观察胸水吸收时间、胸膜增厚变化。结果胸水14天内吸收例数治疗组78.3%，对照组31%（P <0.01）；胸水基本吸收天数，治疗组14.5+2.4d，对照组20.6+4.1d。胸膜肥厚例数2个月后治疗组6.69%，对照组20%（P ＜0.05），6个月后治疗组3.53%，对照组6.97%（P＜0.05）。胸膜结节影2个月后治疗组3.43%，对照组13.63%（P ＜0.05），6个月后治疗组1.09%，对照组6.67%（P＜0.05）。结论结合尿激酶胸膜腔注入能有效缩短胸水吸收时间，减轻胸膜包裹、粘连，减轻胸膜肥厚。
目的：觀察尿激酶胸膜腔註入與傳統單純抗結覈治療結覈性胸膜炎的療效觀察。方法選擇120例滲齣性結覈性胸膜炎，隨機分為治療組、對照組各60例。治療組抗結覈治療同時，間斷胸膜腔穿刺抽胸水後，嚮胸膜腔內註入尿激酶10萬 IU，對照組單純抗結覈治療同時僅間斷胸膜腔穿刺抽胸水治療，分彆觀察胸水吸收時間、胸膜增厚變化。結果胸水14天內吸收例數治療組78.3%，對照組31%（P <0.01）；胸水基本吸收天數，治療組14.5+2.4d，對照組20.6+4.1d。胸膜肥厚例數2箇月後治療組6.69%，對照組20%（P ＜0.05），6箇月後治療組3.53%，對照組6.97%（P＜0.05）。胸膜結節影2箇月後治療組3.43%，對照組13.63%（P ＜0.05），6箇月後治療組1.09%，對照組6.67%（P＜0.05）。結論結閤尿激酶胸膜腔註入能有效縮短胸水吸收時間，減輕胸膜包裹、粘連，減輕胸膜肥厚。
목적：관찰뇨격매흉막강주입여전통단순항결핵치료결핵성흉막염적료효관찰。방법선택120례삼출성결핵성흉막염，수궤분위치료조、대조조각60례。치료조항결핵치료동시，간단흉막강천자추흉수후，향흉막강내주입뇨격매10만 IU，대조조단순항결핵치료동시부간단흉막강천자추흉수치료，분별관찰흉수흡수시간、흉막증후변화。결과흉수14천내흡수례수치료조78.3%，대조조31%（P <0.01）；흉수기본흡수천수，치료조14.5+2.4d，대조조20.6+4.1d。흉막비후례수2개월후치료조6.69%，대조조20%（P ＜0.05），6개월후치료조3.53%，대조조6.97%（P＜0.05）。흉막결절영2개월후치료조3.43%，대조조13.63%（P ＜0.05），6개월후치료조1.09%，대조조6.67%（P＜0.05）。결론결합뇨격매흉막강주입능유효축단흉수흡수시간，감경흉막포과、점련，감경흉막비후。
Objective To observe the effect of urokinase injected into pleural cavity and tuberculosis pleurisy cured in traditional simple anti-tuberculosis method. Methods A total of 120patients suffering from sxudative tuberculosis pleurisy were divided randomly into treatment group(60cases) and matched group(60cases).The pleural cavity of patients in treatment group is being drawn pleural effusion intermittently while being injected into urokinase 100,000IU Compared to the treatment group, the matched group is only punctured to draw liquid from the pleural cativy. The time of pleural effusion absorbed and the change of pleura thickness is observed separately. Results The cases of pleural effusion absorbed within 14 days:The treatment group 78.3%, the matched group 31%(P <0.001).the days of pelural effusion absorbed:The treatment group 14.5+-2.4d,the treatment group after 2months 6.69%, the matched group 21%(P <0.05),The treatment group after 6months 3.53%,the matched group 6.97%(P <0.05).The shadow of pleural nodules:The treatment group after 2 months 3.43%,the matched group 13.63(P<0.05).The treatment group after 6 months 1.09%, the matched group 6.67%(P <0.05). Conclusion These results shows that the injection of urokinase can shorten the time of pleural effusion absorbed effectively and reduce encapsulation, adhesion and the thickness of pleura.
